Featured 13F manager
Pfizer Inc.
New York, NY 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $170M
- 17 Positions
- 2026 Q2
- −28.9% QoQ
- Top 5 78.9%
Pfizer Inc. files a Form 13F. The latest book is 2026 Q2 at $170M, down 28.9% QoQ, led by Allogene Therapeutics, Celcuity, and Arvinas.
Portfolio
top 5 78.9% · top 10 95.7%
- ALLO - Allogene Therapeutics 27.6%
- CELC - Celcuity 17.3%
- ARVN - Arvinas 16.2%
- PYXS - Pyxis Oncology 11.4%
- WVE - Wave Life Sciences 6.4%
- BHVN - Biohaven 4.7%
- CRBU - Caribou Biosciences 4.6%
- Spero Therapeutics 3.1%
- ZNTL - Zentalis Pharmaceuticals 2.3%
- ORIC - Oric Pharmaceuticals 2.1%
- CRDF - Cardiff Oncology 1.8%
- ZURA - Zura Bio · CLASS A 1.7%
- Other 0.8%
AUM over time
Book
| ORIC - Oric Pharmaceuticals | 24.14% | Reduce −11.1% | 4,780,401 | $12.06 | $58M | −595,943 | +$14M |
| ALLO - Allogene Therapeutics | 20.85% | Hold | 22,032,040 | $2.26 | $50M | — | — |
| ARVN - Arvinas | 14.63% | Hold | 3,457,815 | $10.10 | $35M | — | — |
| CELC - Celcuity | 13.13% | Reduce −15.4% | 295,652 | $106.02 | $31M | −53,754 | −$4M |
| ZURA - Zura Bio · CLASS A | 7.05% | Reduce −4.4% | 2,838,913 | $5.93 | $17M | −131,109 | +$1M |
| WVE - Wave Life Sciences | 5.00% | Hold | 1,875,000 | $6.36 | $12M | — | — |
| PYXS - Pyxis Oncology | 3.86% | Hold | 7,032,770 | $1.31 | $9M | — | — |
| CRBU - Caribou Biosciences | 3.50% | Hold | 4,690,431 | $1.78 | $8M | — | — |
| Spero Therapeutics | 2.31% | Hold | 2,362,348 | $2.33 | $6M | — | — |
| BHVN - Biohaven | 1.77% | Hold | 505,645 | $8.37 | $4M | — | — |
| CRDF - Cardiff Oncology | 1.57% | Hold | 2,411,575 | $1.55 | $4M | — | — |
| ZNTL - Zentalis Pharmaceuticals | 0.84% | Hold | 953,834 | $2.10 | $2M | — | — |
| NXTC - Nextcure | 0.64% | Reduce −2.7% | 153,354 | $10.01 | $2M | −4,292 | −$702K |
| AGMB - Agomab Therapeutics | 0.34% | New | 75,000 | $10.85 | $814K | +75,000 | +$814K |
| QTTB - Q32 Bio | 0.31% | Reduce −63.4% | 101,618 | $7.25 | $737K | −176,159 | −$185K |
| BOLT - Bolt Biotherapeutics | 0.06% | Hold | 31,305 | $4.38 | $137K | — | — |
| DNA - Ginkgo Bioworks · CL A | 0.01% | Hold | 2,928 | $5.93 | $17K | — | — |
| Senseonics | 0.01% | Hold | 2,171 | $6.56 | $14K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ANTX - An2 Therapeutics | 0.34% | Exit | 0 | $1.14 | $815K | −715,295 | −$815K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 17 | $170M | −28.9% | 13F-HR | 8/13/2026 | 000007800326000102 |
| 2026 Q1 | 18 | $239M | +1.3% | 13F-HR | 5/12/2026 | 000007800326000064 |
| 2025 Q4 | 18 | $236M | −46.0% | 13F-HR | 2/12/2026 | 000007800326000013 |
| 2025 Q3 | 21 | $437M | — | 13F-HR | 11/13/2025 | 000007800325000161 |
About
Pfizer Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2